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Infection with Plasmodium parasites (malaria) contributes greatly to morbidity and mortality 
in affected areas. Interaction of the protozoan with the immune system has a critical role in 
the pathogenesis of the disease, but may also hold a key to containing parasite numbers 
through specific immune responses, which vaccine development aims to harness. A central 
player in the generation of such immune responses is the dendritic cell. However, 
Plasmodium parasites appear to have profound activating and suppressing effects on 
dendritic cell function, which may enhance immunopathology or facilitate the parasite’s 
survival by depressing beneficial immunity. Furthermore, immune responses to other 
infections and vaccines may be impaired. A greater understanding of the effects of the 
parasite on dendritic cells will contribute to insight and potential defeat of this 
infectious disease.
The morbidity and mortality caused by Plasmo-
dium infection makes it one of the most signifi-
cant infectious diseases. There are an estimated
500 million cases of malaria annually, and of the
1 million fatalities the majority are children
under 5 years in sub-Saharan Africa. Globally,
disease inflicts a massive socioeconomic burden
on the numerous affected regions in tropical and
subtropical countries.
The complex life cycle of the protozoan para-
site has provided a range of subject areas for
research that attempts to understand better the
biology of the pathogen and how it interacts
with the immune system. Host responses against
the blood stage of the parasite, both the innate
and adaptive arms of the immune response, have
been shown to make a major contribution to dis-
ease etiology [1]. The dendritic cell (DC) is a cen-
tral player in the immune system, critically
linking the innate and adaptive arms and thus
dictating not only the generation of antiparasite
T cells and antibodies, but also the quality
(cytokine or antibody profile) of these responses.
Thus, the interaction between the parasite and
DCs, the subject of this article, is critical to the
generation of parasite-specific adaptive immune
responses. Such responses may impart protection
from infection or disease when generated by
natural exposure or by vaccination [2]; or con-
versely, may contribute to adverse immuno-
pathology. It is important to bear in mind that
studies on DC function in conjunction with
Plasmodium have examined responses of differ-
ing DC types (myeloid and plasmacytoid), of
human or murine origin, infected with different
Plasmodium species, both in vivo and in vitro [3].
However, despite disparate data, a picture begins
to emerge that may reconcile the wide range of
heterogeneous studies. 
Background on dendritic cells 
DCs are mononuclear leukocytes that originate in
the bone marrow. Their precursors circulate in the
blood and localize to most tissue types where they
differentiate into phagocytic cells (immature DCs
or related cells) that capture antigens in their
vicinity [4]. They are also able to recognize a wide
range of molecules, particularly those derived
from pathogens that bind sets of receptors includ-
ing scavenger receptors and the Toll-like
receptor (TLR) family [5]. In this way they are able
to sense a broad range of situations in the host
that require a reaction, sample associated antigens
and instigate an appropriate immune response,
such as cell-mediated immune responses for intra-
cellular pathogens or regulatory responses for
self/harmless antigens. Indeed, DCs have a unique
ability amongst antigen-presenting cells (APCs) to
prime naive T cells. Once they have ingested
foreign antigen and been stimulated, DCs mature
and change their functions from antigen uptake in
tissues, to antigen processing and presentation,
together with migration to local lymph nodes
through the expression of homing molecules (e.g.,
chemokine receptor CCR7). Complex antigen-
processing pathways allow DCs to present anti-
gen-derived peptides both by major histo-
compatibility complex (MHC) class I molecules
to CD8+ T cells and by MHC class II molecules to
CD4+ T cells, both molecules of which are upreg-
ulated upon activation. Their activation also gives
rise to expression of costimulatory molecules,
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chiefly CD80 and CD86, which are critical to
priming naive T cells, together with the secretion
of cytokines that promote cell-mediated immunity,
such as IL-12 or type I interferons. 
Subtypes of DC exist based on myeloid or
plasmacytoid characteristics (mDCs and pDCs,
respectively). Human pDCs are characterized by
expression of high levels of IL-3 receptor
(CD123) and the ability to secrete large amounts
of IFN-α, whilst mDCs are characterized by
expression of CD11c, CD1c or CD83 and nota-
bly secrete IL-12. Murine mDCs are also
CD11c+ but express various combinations of
CD4 and CD8α. Murine pDCs possess low lev-
els of CD11c and are B220+. Differential TLR
expression by DCs indicates further functional
heterogeneity. Typically, pDCs possess TLR7
and 9 which are involved in the recognition of
bacterial DNA CpG motifs and viral-derived
dsRNA, whereas mDCs recognize bacterial and
fungal structural or membrane molecules
(e.g., lipopolysaccharides) via TLR2 and 4. Cer-
tain types of DC are also able to present native
antigen to naive B cells [6], thus instigating their
activation to produce specific antibodies.
Malaria life cycle
Human hosts become infected when a female
anophelene mosquito carrying plasmodial species
takes a blood meal. Out of four major species to
infect man, Plasmodium falciparum presents with
the most severe and life-threatening diseases and
receives most attention in clinical and basic
human research. There are also mouse-specific
Plasmodium species used to model infection.
Sporozoites that exit from the mosquito salivary
gland during feeding are injected (a mean of
123 sporozoites, as shown in mouse models [7])
into the host’s dermis from which they migrate
into the circulation via blood or lymph [8] and
home to the liver within minutes (Figure 1).
Within hepatocytes the parasite replicates asexu-
ally (and asymptomatically) into the merozoite
stage, typically over a 7-day period for
P. falciparum, and amplifies in number from a sin-
gle sporozoite to tens of thousands of merozoites.
Hepatocytes release phagocyte-resistant vesicles
containing merozoite progeny into the blood-
stream [9], during which the initial effects on the
immune system, chiefly an inflammatory
response and fever, may be observed owing to
released plasmodial molecules (e.g., glycophos-
phatidyl inositol anchors [10]). Merozoites subse-
quently infect red blood cells (RBCs) giving rise
to schizonts over 48-hour cycles for P. falciparum
(but differing for other species), which release fur-
ther merozoites together with other molecules and
metabolites (e.g., hemozoin, a malarial by-product
of RBC pigment). Hemozoin, together with mol-
ecules expressed by infected RBCs (iRBCs), fur-
ther stimulate inflammatory immune responses,
notably TNF-α and acute-phase proteins. Serious
sequelae include the sequestration of iRBC in the
blood vessels in the brain contributing to cerebral
malaria, which is fatal in approximatley 20% of
cases. Finally, a proportion of the merozoites
develop into gametocytes, which are ingested by a
feeding mosquito, in the gut of which they com-
bine to give rise to ookinetes. Sporozoites ulti-
mately develop, which migrate to the salivary
gland where they can be injected into the host and
start the cycle again. 
Immune response against malaria
There is much evidence that immunity to
Plasmodium infection generated by natural expo-
sure, or through vaccination, is able to mediate a
significant reduction in disease incidence,
despite the large array of target antigens and
their genetic variability [2,11]. However, immune
responses are also responsible for infection-asso-
ciated pathology [1,12], and require careful tuning
between beneficial and pathological responses to
allow survival of the host. The stage of the life
cycle is critical when considering immune
responses. The liver stage does not generate overt
systemic inflammatory responses nor disease
because a limited number of hepatocytes are
infected, and liver-stage antigen is relatively lim-
iting. Antibody responses against sporozoites can
reduce hepatocyte infection, under certain cir-
cumstances such as vaccination [13], rather than
natural immunity. Importantly, we and others
have been able to demonstrate IFN-γ T-cell
responses generated by natural exposure that
confer a degree of resistance to infection [14,15].
Furthermore, vaccinations with viral vectors
encoding liver-stage antigens generate protective
IFN-γ CD4+ and CD8+ T-cell responses [16].
Although T-cell responses against the blood
stage of infection have shown some association
with protection in a vaccination study [17],
antiblood stage antibodies appear to be the main
responses that confer protection in endemic
regions [18–20], and are the aim of numerous vac-
cine approaches [2]. The success of malaria vac-
cines in such areas depends on vaccinees
possessing a fully functioning immune system,
in particular their DCs. Immunity to other
infections and vaccines may also be impaired.
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Dendritic cells & malaria
There is disparate and often contradictory data on
responses of DCs to Plasmodium parasites (Table 1),
and their clear description benefits from describing
human and mouse responses separately. 
Despite early suggestions that malaria infection
might suppress immune responses [21], particularly
APC function [22], the first demonstration of para-
sites influencing human DC function came in
1999. Our study showed that malaria iRBCs were
able to bind to human mDCs in vitro and inhibit
maturation and their ability to stimulate T cells [23].
These findings were taken further to show that this
process involved the binding of iRBC to CD36 on
DCs [24], which is a multiligand scavenger receptor
known to bind apoptotic cells, against which
immune responses are often not desired. More
recent in vitro studies have shown additional sup-
pressive effects not involving parasite binding to
CD36 but implicating chondroitin sulphate-A,
and also noncontact mechanisms [25]. Further-
more, this study showed that high doses of para-
sites (100 iRBC:1 DC) were suppressive and
caused DC apoptosis, whilst low doses (10:1) acti-
vated DCs. The physiological relevance of these
doses remains unclear. Hemozoin, a byproduct of
malarial infection of RBCs, was shown to inhibit
maturation of human mDCs [26], whilst pDCs
responded to schizont extract by producing
IFN-α, upregulating CD86 and induced
γδT-cells that secrete IFN-γ rather than
conventional T cells [27]. In vivo, children suffer-
ing with acute malaria infection show reduced
expression of HLA-DR (MHC class II) on mDCs
and increased frequencies of BDCA-3-
expressing DCs, possibly an IL-10-suppressed
phenotype [28,29]. Both these findings suggest
depressed DC activity.
Figure 1. Effect of Plasmodium on dendritic cells.
 
Mosquitoes transmit sporozoites which home to liver cells and develop into vast numbers of merozoites. Upon release these infect red 
blood cells. Early during infection when parasite density is low, DCs become activated (via TLR9) and can generate T cells and associated 
immune responses. Later during infection when parasite densities are high, DCs may be overstimulated via CD36 or TLR9, or due to high 
levels of TNF-α, and may be refractory to activation, ‘regulatory’ and/or may produce IL-10. They also may become apoptotic. T cells and 
associated immune responses are suppressed or reduced. 
DC: Dendritic cell; TLR: Toll-like receptor.
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In mouse studies, using murine-compatible
Plasmodium species, iRBCs (schizonts or lysates
thereof ) were able to stimulate murine mDCs to
produce IL-12 and elicit T-cell activation [30], as
well as DC surface expression of CD40 and
CD86 and migration to T-cells zones in lym-
phoid tissue in vivo [31]. In contrast with such
activation, another group showed hemozoin to
impair murine DC function in lymphoid tissue,
particularly DC:T-cell clustering, and generated
poorly functional T cells [32,33]. Conversley,
another study showed that purified hemozoin
enhanced murine DC maturation and IgG2a
generation, an effect that seemed to be depend-
ant on TLR9 and MyD88 signaling [34]. It has
been more recently suggested that it is malarial
DNA bound to hemozoin, and acting via TLR9,
that activates DCs [35]. A specific role for DCs [36],
and of MyD88 [37], in proinflammatory
responses and disease has also recently been
demonstrated, as well as the cAMP regulation of
IL-6 in a transcriptome profile of DCs stimulated
with Plasmodium [38].
The qualitative nature of the antimalaria adap-
tive immune response is essentially a result of the
interaction of DCs with malaria. The first
encounter that DCs may have with the parasite is
following the injection of sporozoites by mosqui-
toes into the dermis where they can be taken up
by local DCs and prime protective T cells in
draining lymph nodes [39]. However, the most
profound effects on DCs occur during the blood
stage of infection. Murine studies highlight that a
particular DC subtype (CD8-) is most efficient in
priming CD4+ T cells during such acute infection
[40], whereas CD8+ DCs cross-present and prime
CD8+ T cells early during infection. Cross-presen-
tation is abrogated as parasitemia develops owing
to a systemic inflammatory response [41]. Others
reported that presentation of malarial antigens to
CD8+ T cells may induce their cell cycle arrest,
associated with a partial defect in DC function
[42,43]. However, co-administration of a DC-spe-
cific chemokine, DC-CK1, may circumvent such
a phenomenon [44].
The capacity of murine splenic CD11c+ DCs
to become activated and to present antigen to
T cells is believed to change over the course of
infection [25,40,42], and this observation may
reconcile some of the heterogenous findings that
showed either activation or suppression of DC
function associated with malaria. In simple
terms, early on in infection when parasite density
is relatively low, IL-12-mediated mechanisms
induce IFN-γ-producing CD4+ T cells. This DC
phenotype may be maintained over the entire
course of infection with nonlethal strains of
Plasmodium [45], although it is unclear how lethal
and nonlethal strains differ with respect to the
immune response they generate, and the influence
of dose. Later, when parasite densities are peaking,
DCs may become refractory to TLR and other
signaling events, possibly due to overstimulation
or due to TNF-α [46,47], thus abrogating IL-12
and TNF-α secretion, and as capacity to produce
IL-10 increases. While secretion of IL-10 may
reduce inflammatory responses, a desirable effect
when linked to clinical immunity [1], specific
immune responses to malaria antigens as well as to
other infections and vaccines may be reduced.
Most recently, Plasmodium yoelii infection of mice
has shown a prevalence of ‘regulatory’ CD11clow,
CD45RBhigh DCs in the spleen, overtaking con-
ventional CD11chigh DCs, which induce
IL-10-secreting T cells [48]. Such DCs may also
secrete TGF-β and prostaglandin PGE2 and
IL-10 [49], thus inhibiting generation of T cells;
against liver stage in this study. The suppression of
DC function by iRBCs mirrors that produced by
endotoxin LPS [48], and may be part of a negative
feedback or tolerance mechanism occurring at
high parasite dose.
A human study that supports the dose theory
showed that very low doses of iRBC generated
T-cell responses that were protective against sub-
sequent blood-stage challenge [17]. Of further rele-
vance, we have recently demonstrated that
malarial parasitemia in Kenyan volunteers during
vaccination trials with viral vectors encoding
liver-stage antigens gave rise to reduced T-cell
responses [50]. We speculate that such an effect
may be in part via parasite-induced suppression of
DCs. A possibility for vaccination, therefore, is to
administer a course of antimalarial drugs prior to
and during the vaccination regimen in trials in
endemic regions.
The generation of antigen-specific regulatory
T cells (FOXP3+ and TGF-β+) following experi-
mental malarial infection in naive individuals
suggests that modulated DCs are involved in
priming of T cells, although suppressive in
nature and possibly promoting parasitemia [51].
We have recently identified deficiencies in
blood stage-specific T-cell memory development
during similar infection [Todryk S, Walther M, Bejon P
et al., Manuscript in preparation].
Last, DCs have recently been implicated in
intricate cross-talk with natural killer cells to
produce IFN-γ in response to iRBCs and to
maintain DC maturity [52]. 
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Conclusion & future perspective
DCs are at the heart of the immune system, sensing
and initiating immune responses to ‘dangerous’
infectious microbes, or harmless/self antigens,
which are ultimately critical for the survival of the
host. For the complex disease that is malaria, it is
essential that immune responses are generated
within the correct boundaries so as to be protective
against parasitemia without causing immuno-
pathology or disease. The plasticity of DC pheno-
types and function enables the existence of such
immunity, through parasite recognition, and is
affected by parasite dose and previous exposure.
Low-dose immunization may be pursued in vacci-
nation [17] or through intermittent preventive treat-
ment with antimalarial drugs [53], which may allow
the generation of immunity by keeping down para-
site numbers, thus avoiding high-dose suppression.
Furthermore, drugs could be administered in con-
junction with vaccine trials to avoid immune
suppression by high malarial parasite numbers. 
A picture is beginning to form as to how DCs
may orchestrate antimalaria responses, but differ-
ences in the way humans and mice recognize and
respond to stimuli, such as DNA vaccines [54],
means that murine findings may not always apply
directly to humans. In addition, in vitro studies,
whilst being valuable reductionist approaches,
breaking down the DC–malaria interaction, may
not reveal the real in vivo multifactorial situation.
Further clinical studies are therefore required in
humans, examining DCs and associated immune
responses in both experimental and natural infec-
tion, in order to provide more clues for manipula-
tion of such responses in prophylactic and
therapeutic immune-based intervention. The com-
plicated nature and expense of such studies mean
that it may take several years before knowledge of
the interaction between DCs and Plasmodium
impacts directly on clinical developments. 
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Executive summary
Introduction
• There are 500 million cases of malaria a year, with 1 million of these being fatal.
• The immune response contributes to disease etiology.
• Dendritic cells are central players in immune responses.
Background on dendritic cells
• Dendritic cells (DCs) are phagocytic antigen-presenting cells.
• DCs are sentinels of immune system detecting pathogens.
• Myeloid and plasmacytoid types of DCs exist.
• DCs direct the generation of specific or adaptive immune responses.
Immune response against malaria
• Immune responses may be protective or may mediate disease.
• Antibodies and T-cell responses are targets for vaccines.
• Functional DCs are required.
Dendritic cells & malaria
• DCs are suppressed by infected red blood cells via CD36.
• DCs are activated and suppressed by pigment byproduct hemozoin.
• Low parasite dose causes DC activation, and high parasite dose causes DC suppression.
• High parasite dose may cause a ‘regulatory’ DC phenotype and DC apoptosis.
Conclusion & future perspective
• DC flexibility allows immune activation and suppression required for host survival.
• Parasite density controlled by drugs may enhance natural immunity or that generated by vaccines.
• Despite their obvious value, we should avoid over-reliance on in vitro and murine studies.
• It will take some time before appropriate human studies can impact on clinical developments.
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